Thaddeus Stappenbeck received his B.A as a member of the Integrated Science Program at Northwestern University, as well as his M.D and Ph.D. from Northwestern University Medical School. He trained in anatomic pathology at the Washington University School of Medicine. He was hired as an assistant Professor in the Department of Pathology and Immunology at Washington University, where he moved up the ranks to Division Chief of Laboratory and Genomic Medicine. Dr. Stappenbeck currently serves as the chair of Inflammation and Immunity at Cleveland Clinic, where his research program focuses on determining the root causes of inflammatory and infectious diseases with the goal of developing new therapies for these diseases. His lab has defined stages and mechanisms of intestinal repair leading to a lead compound for a novel therapy for inflammatory bowel disease and idiopathic pulmonary fibrosis, determined mechanisms for the effects of intestinal microbes on repair and created a cell culture system for human intestinal stem cells that is used by labs around the world. He moved to Cleveland Clinic to partner with the world class clinicians and scientists in this institution to accelerate the translation of discoveries in immunology, developmental biology, cell biology, and microbiology to new concepts for therapy in inflammatory disease. He serves on scientific advisory boards for Science Immunology, as well as several companies in the area of inflammatory bowel diseases. He is a member of ASCI/APP. He has collaborated extensively with many other investigators and published over 160 articles in high impact journals, while successfully training numerous physician-scientists and scientists and encouraging them to inflammatory and infectious disease. His lab has been supported by broad portfolio including the National Institute of Health, Crohn's Colitis Foundation of America, Helmsley Trust, American Asthma Foundation, Rainin Foundation, Broad Medical Research Program, the Gates Foundation, the Pew Foundation and pharmaceutical companies including Genentech, Pfizer, Janssen and Boehringer-Ingelheim.